AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RMD

Farrell Michael J. sold $1.1M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $226.33 ($1.13M total) on 2026-10-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Oct 8, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Bearish
medium confidence
Mentioned
$RMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDBearishLow
01

Why it matters

The sale reduces insider ownership and may be interpreted as a negative signal, but the size is modest relative to total holdings.

02

Market read

A modest insider sell by the CEO, disclosed via Form 4, provides a low‑to‑moderate trading signal.

03

What to watch

Potential upcoming earnings or product news that may offset the sell‑off.

Relevance 5/10Novelty 5/10Timing: after-hours filing today

Background

Form 4 filings are primary disclosures of insider transactions required by the SEC.

Company-level read

Ticker impact

$RMDBearishMedium confidence
Context

CEO Michael J. Farrell sold 4,991 shares for $1.13M via a 10b5‑1 plan, reducing his stake to 479,803 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $1.1M sale by the chairman/CEO is material but not large enough to trigger a sharp move; traders may watch for short‑term weakness.

Market effects

Sector

Minimal impact on the broader medical device sector; insider activity is company‑specific.

Regional

No regional effect; the filing is U.S.‑focused.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Person
    Michael J. Farrell

    Chairman and CEO of ResMed Inc.

  • Company
    ResMed Inc.

    Medical device manufacturer listed on NYSE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com